Bacteriophages Clear Acne-Causing Bacteria and Rebuild the Skin Microbiome, Trial Finds

Acne affects more people worldwide than any other skin disease, yet the therapeutic toolkit has barely changed in decades. A new randomized, double-blind, placebo-controlled trial published in the Journal of Drugs in Dermatology by Prooyen NV et al. suggests that bacteriophages, viruses that selectively kill bacteria, can reduce Cutibacterium acnes on the skin, improve clinical lesion counts, and, perhaps most intriguingly, increase the diversity of the skin microbiome after just eight weeks of treatment.

Phage therapy reduces Cutibacterium acnes and improves acne scores

The trial enrolled 90 participants, males and females between 12 and 35 years old, with mild to moderate acne. They were split into three arms: placebo, phage alone, and phage combined with salicylic acid (SA). Clinic visits at baseline, week 4, and week 8 collected VISIA imaging, lesion counts, Investigator Global Assessment (IGA) scores, and microbiome samples. Both the phage-only and phage-plus-SA arms showed statistically significant improvement over baseline at eight weeks (P<0.05). Phage application also produced a statistically significant decrease in C. acnes on the skin compared to placebo (P<0.05). The treatment demonstrated an excellent safety profile throughout.

The core mechanism here is worth unpacking. Bacteriophages are viruses that infect and destroy specific bacterial species. Unlike broad-spectrum antibiotics, they can be selected to target C. acnes without touching the rest of the skin flora. As prior research on phage specificity in acne has noted, that precision is a key advantage: you eliminate the problem organism without collateral damage to beneficial microbes. The C. acnes phages characterized to date appear to be strictly lytic, meaning they destroy host cells rather than integrating into bacterial DNA, which is the preferred mode for a therapeutic application.

Microbiome diversity gain suggests durable, long-term skin benefits

The finding that draws the most attention is not the bacterial kill, but what happened after it. Phage use over eight weeks significantly increased skin microbiome diversity, a result that researchers suggest could translate into durable, long-term skin health benefits. A more diverse microbiome is generally associated with a more resilient skin barrier and lower susceptibility to flare-ups.

This matters because the global burden of acne vulgaris is substantial and still growing: prevalence among adolescents and young adults aged 10 to 24 has increased from 1990 to 2021, meaning a huge population has a condition that current treatments address imperfectly. Standard options such as benzoyl peroxide, retinoids, and antibiotics reduce bacteria or normalize cell turnover, but none of them are associated with rebuilding microbiome diversity. Phages, by selectively reducing C. acnes and allowing other species to re-establish, could offer something qualitatively different. Immunomodulatory effects from phage-driven bacterial lysis may further reinforce this by reducing the inflammatory signaling that sustains acne lesions.

How the double-blind design strengthened the evidence

The study's credibility rests on its design. A randomized, double-blind, placebo-controlled structure is the gold standard for separating a real treatment effect from expectation bias, and it is still relatively rare in phage therapy research, where most evidence has come from case series or small open-label studies. Phage therapy randomized controlled trials are now appearing more frequently across different infection types, but the eight-week window, the three-arm structure, and the combination of subjective scoring (IGA) with objective microbiome sampling make this trial methodologically more rigorous than most preceding acne phage work. Delivery is also a non-trivial consideration: the pilosebaceous unit, the hair follicle and sebaceous gland where C. acnes thrives, is notoriously difficult to reach topically, and successful delivery to that site is critical for efficacy.

Open questions about resistance, pharmacokinetics, and long-term safety

The trial's limitations are real and the authors acknowledge them. The study ran for only eight weeks with 90 participants, which is enough to detect a signal but not enough to establish how durable the microbiome diversity gain is, or whether it translates to sustained remission over months or years. The biological challenges of phage therapy development are well documented: bacteria can evolve resistance to phages, the pharmacokinetics of topically applied phages are not fully characterized, and the long-term immune response to repeated phage exposure on human skin is not yet understood. Large-scale randomized controlled trials and deeper mechanistic studies are still required before phage therapy can be considered for routine clinical use.

The path from promising trial to approved acne treatment

Assuming further trials confirm the eight-week findings at scale, phages could enter the acne treatment landscape as either an adjunct to existing therapies or a standalone option for patients who prefer to avoid antibiotics. The antibiotic resistance argument is increasingly relevant: C. acnes resistance to erythromycin and clindamycin has been rising for years, and phages carry a low intrinsic risk of driving resistance because any bacteria that evolve to evade a phage can often be countered with a different phage strain. The regulatory path, however, remains complex. Phage therapy faces regulatory and manufacturing hurdles that standard small-molecule drugs do not: phages are living organisms, batch consistency is technically demanding, and most regulatory frameworks were not designed with them in mind.

None of that diminishes the significance of what this trial demonstrated. A targeted, microbiome-preserving intervention that reduces C. acnes, improves clinical scores, and increases skin diversity over eight weeks is a meaningful result. Whether it scales into a licensed product depends on what the next generation of larger trials finds, but the direction is clear enough to watch closely.

Evidence rating

EMERGING — 76/100

Caveats:

• Funding source was not disclosed by the authors.
• Study population was limited to mild-to-moderate acne in participants aged 12–35; findings may not generalize to other severities or age groups.
• This is a single trial; independent replication is needed before conclusions can be drawn about long-term skin health benefits.
• Microbiome diversity increase is a surrogate marker — a causal link to durable clinical outcomes has not been established.

Randomized double-blind placebo-controlled trial (n=90, 8 weeks). Demonstrates statistically significant reductions in C. acnes burden and improvements in lesion counts, with increased skin microbiome diversity in treatment arms versus placebo. Funding was not disclosed, limiting conflict-of-interest assessment. This is a single trial and independent replication is required before the diversity findings can be interpreted as evidence of durable long-term benefit.